Search
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters. … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Procaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedProcaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … [A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus
Iron sucrose
go.drugbank.com/drugs/DB09146ApprovedInvestigationalIron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis
Valerian
go.drugbank.com/drugs/DB13196ApprovedValerian is a food ingredient permitted for direct addition to food for human consumption as a natural flavoring substance.
Mixtures: Dormiphen Au NaturelCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigational[A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. … The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
Products: ZONISAMIDE DOC GENERICINorepinephrine
go.drugbank.com/drugs/DB00368ApprovedInvestigationalIt is also found in plants and is used pharmacologically as a sympathomimetic.
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]